Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:57 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
NCT04955938 · University of Chicago · PHASE1 · withdrawn · last registry update 2024-07-31 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “unable to accrue” | – | Registry record, University of Chicago |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IDH1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-07-20Phase 3 first posted: Stichting Hemato-Oncologie voor Volwassenen Nederland, Venetoclax 400 + Placebo (NCT07075016)
- 2025-06-26Results posted on the registry: Forma Therapeutics, Inc., FT-2102 (olutasidenib) + Azacitidine (NCT02719574)
- 2025-02-06Results posted on the registry: Jason J. Luke, MD, ivosidenib and nivolumab (NCT04056910)
- 2025-02-05Phase 3 first posted: European Organisation for Research and Treatment of Cancer - EORTC, Vorasidenib + Vorasidenib Placebo (NCT06809322)
- 2025-01-17Phase 3 first posted: Servier, Vorasidenib + Placebo (NCT06780930)
- 2024-12-03Phase 3 first posted: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, High intensity therapies + Low intensity therapies (NCT06713837)
- 2024-06-20Phase 3 first posted: Institut de Recherches Internationales Servier, Ivosidenib + Azacitidine (NCT06465953)
- 2024-06-14Results posted on the registry: Hoffmann-La Roche, Alectinib + Vismodegib (NCT03498521)
- 2024-05-06Also stopped (terminated): Academic and Community Cancer Research United, Cisplatin + Gemcitabine (NCT04088188)
- 2024-05-02Results posted on the registry: Academic and Community Cancer Research United, Cisplatin + Gemcitabine (NCT04088188)
- 2023-11-24Results posted on the registry: Institut de Recherches Internationales Servier, Vorasidenib + Matching Placebo (NCT04164901)
- 2023-11-13Phase 3 first posted: Servier Bio-Innovation LLC, Ivosidenib 500mg + Placebo (NCT06127407)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision